Skip to main content

Table 1 Levels of galectin-1 in the sera of EOC patients and healthy controls

From: Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients

  

galectin-1 (ng/ml)

Diagnosis

No. of patients

Median

5th percentile

95th percentile

Range

P

Healthy donors

70

88

30

174.3

30–231

0.15a

Benign Gyn Tumor

60

78

32.5

169.8

30–229

0.38b

Other Gyn

      

 Malignancies

50

92

33.5

176.5

30–240

0.042c

 Histologies

      

 Serous

105

191

31.5

760

  

 Mucinous

45

202

34.5

812

  

 Endometroid

37

179

29.8

745

  

 Clear cell

23

182

30.2

789

 

0.784d

 EOC

140

149

34.5

828

30–950

 

 Nonmetastatic

45

69

36.2

169.3

30–163

 

 Metastatic

95

370

40

840

30–950

0.034e

EOC stage

      

 I

44

69

36.2

169.3

30–163

 

 II

35

260

39

370

30–390

 

 III

46

352

180

590

170–610

 

 IV

15

630

505

890

480–950

0.041f

  1. a-f Ps refers to the difference between the cohorts of healthy individuals and EOC patients a, or the difference of EOC patients and patients with benign gynecologic tumors b, or the difference of EOC patients and patients with other gynecologic malignancies c, or between the groups of EOC patients with different histology d, or the difference between the groups of patients with nonmetastatic and metastatic disease e or the groups of patients with stageI- IVf. EOC epithelial ovarian cancer, Gyn gynecologic
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us